A Prospective Study of Diagnosis and Therapeutics in Intraocular Malignant Lymphoma

A Prospective Study of Diagnosis and Therapeutics in Intraocular Malignant Lymphoma - A Prospective Study of Diagnosis and Therapeutics in Intraocular Malignant Lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007821

Enrollment

150

Registered

2012-04-23

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveitis suspected as Intraocular Malignant Lymphoma

Interventions

1)Primary Intraocular lymphoma (IOL) only with primary systemic malignant lymphoma (ML): intravitreal injection of 0.4mg of MTX(totally 10times, once a week for 2 months and once a month for 2 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age: 20-75 years old Selection criteria 1) cases with uveal inflammation, which is suspected as intraocular malignant lymphoma, and vitreous biopsy was done for diagnostic purposes. 2) Diagnostic criteria for intraocular lymphoma is as follows. (a) the vitreous fluid cytology (class 5) 3 points (Class 4) 2 points (Class 3) 1 point (b) IL-10/IL-6 (>1) or IL-10> 50pg/ml) 2 points (c) IgH monoclonality 2 points (d) FACS (distribution of kappa and lambda) 2 points (e) funduscopic findings that are characteristic of intraocular lymphoma (the aurora-like vitreous opacity or patchy cell infiltration of the retina (often with serous retinal detachment)). 1 point (f) the pathological diagnosis of malignant lymphoma of the eye or other organs before. 1 point If the sum of these 6 items is more than 4 points, we diagnose intraocular lymphoma. 3) adaptation of the treatment protocol: Ccr> 50

Exclusion criteria

Exclusion criteria: Except for performance status 4

Design outcomes

Primary

Measure	Time frame
Diagnostic efficacy (sensitivity) of the diagnostic criteria Local recurrence ratio, systemic recurrence ratio, overall survival, progression-free survival	—

Secondary

Measure	Time frame
Classification of the papanicolaou staing of the vitrecous specimens, concentration of IL10/IL-6 of vitreous samples, IgH monoclonarity, final visual acuity, site of systemic dissemination, term during therapy and recurrence	—

Countries

Japan

Contacts

Public ContactRIE TANAKA

University of Tokyo Hospital Ophthalmology

rtanaka-ymn@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026